Richard A. Franklin

Employment

• East Carolina University Brody School of Medicine Assistant Dean of Graduate Studies
  2015 - Present
• East Carolina University Brody School of Medicine Associate Professor
  2002 - Present
• East Carolina University Brody School of Medicine Assistant Professor
  1996 - 2002

Education

• University of Illinois Ph.D.
  ? - 1989
• University of Illinois M.S.
  ? - 1986

Projects & Funding

Projects & funding information is unavailable.

Publications (107)

• Signaling intermediates (MAPK and PI3K) as therapeutic targets in NSCLC
  Current Pharmaceutical Design 2014 76 citations DOI: 10.2174/13816128113196660763
  +Save
• Increased NGAL (Lnc2) expression after chemotherapeutic drug treatment
  Advances in Biological Regulation 2013 14 citations DOI: 10.1016/j.jbior.2012.09.004
  +Save
• Advances in targeting signal transduction pathways
  Oncotarget 2012
  +Save
• Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the natural plant product berberine
  Cell Cycle 2012 27 citations DOI: 10.4161/cc.22786
  +Save
• Novel approaches to target cancer initiating cells-Eliminating the root of the cancer
  Advances in Biological Regulation 2012 13 citations DOI: 10.1016/j.advenzreg.2011.09.011
  +Save
• Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: How mutations can result in therapy resistance and how to overcome resistance
  Oncotarget 2012
  +Save
• Involvement of Akt and mTOR in chemotherapeutic and hormonal-based drug resistance and response to radiation in breast cancer cells
  Cell Cycle 2011 92 citations DOI: 10.4161/cc.10.17.17119
  +Save
• Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy
  Oncotarget 2011
  +Save
• Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: Rationale and importance to inhibiting these pathways in human health
  Oncotarget 2011
  +Save
• Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy
  Leukemia 2011 264 citations DOI: 10.1038/leu.2011.66
  +Save